Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D Global BiotechROCO:6808 70 PS Ratio is 15.39 as of Jul. 26, 2026, which is 86% below its 10-year median of 106.61. GuruFocus rates ROCO:6808 with a GF Score™ of 70/100 and a GF Value™ of NT$186.52 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 930 Biotechnology companies, 3D Global Biotech ranks worse than 61.51% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, 3D Global Biotech's share price is NT$40.15.
3D Global Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.61. Hence, 3D Global Biotech's PS Ratio for today is 15.39.
The historical rank and industry rank for 3D Global Biotech's PS Ratio or its related term are showing as below:
ROCO:6808'
s PS Ratio Range Over the Past 10 Years
Min: 9.35 Med: 106.61 Max: 248.01
Current: 15.39
During the past 9 years, 3D Global Biotech's highest PS Ratio was 248.01. The lowest was 9.35. And the median was 106.61.
ROCO:6808's PS Ratio is ranked worse than 61.51% of 930
companies
in the Biotechnology industry
Industry Median: 9
vs ROCO:6808: 15.39
3D Global Biotech Inc revenue per share is in decline over the past 12 months.
During the past 12 months, the average Revenue per Share Growth Rate of 3D Global Biotech was -30.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was 120.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was 82.20% per year.
During the past 9 years, 3D Global Biotech's highest 3-Year average Revenue per Share Growth Rate was 164.40% per year. The lowest was -11.60% per year. And the median was 12.25% per year.
Back to Basics: PS Ratio
3D Global Biotech (ROCO:6808) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
3D Global Biotech PS Ratio Related Terms
3D Global Biotech PS Ratio Historical Data
* Premium members only.
The historical data trend for 3D Global Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6808 vs VRTX, REGN, ALNY: PS Ratio Comparison
For the Biotechnology subindustry, 3D Global Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Global Biotech PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Global Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where 3D Global Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
3D Global Biotech's Share Price of today is NT$40.15.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Global Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was NT$2.61.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
3D Global Biotech (ROCO:6808) has a PS Ratio of 15.39 as of Jul. 26, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 3D Global Biotech and its competitors. This is 86% below median its historical median of 106.61. Over the past decade, 3D Global Biotech's PS Ratio has ranged from 9.35 to 248.01. According to the industry distribution chart, 3D Global Biotech ranks #572 out of 930 companies in the Biotechnology industry, placing it in the top 61.5%.
Is 3D Global Biotech's PS Ratio too high?
3D Global Biotech's current PS Ratio of 15.39 is 86% below median its 10-year median of 106.61. Over the past 10 years, this metric has ranged from a low of 9.35 to a high of 248.01. The Biotechnology industry median PS Ratio is 9.00. 3D Global Biotech's value of 15.39 is 71% above this industry median. Based on the distribution chart, 3D Global Biotech ranks #572 out of 930 companies in the Biotechnology industry, which is below the industry midpoint. Overall, 3D Global Biotech has a GF Score™ of 70/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Global Biotech's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Global Biotech ranks #572 out of 930 companies for PS Ratio. This places 3D Global Biotech in the lower half of its industry. The industry median PS Ratio is 9.00. 3D Global Biotech's value of 15.39 is 71% above this benchmark. Historically, 3D Global Biotech's own PS Ratio has ranged from 9.35 to 248.01 over the past decade. While the company's 10-year median is 106.61 vs. the industry median of 9.00, 3D Global Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.00, based on 930 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Global Biotech's current PS Ratio of 15.39 is 71% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 3D Global Biotech and its competitors. For the Biotechnology industry, the median PS Ratio is 9.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Global Biotech's current PS Ratio is 15.39, which is 86% below median its own 10-year median of 106.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Global Biotech stock overvalued right now?
Based on GuruFocus' analysis, 3D Global Biotech (ROCO:6808) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$186.52, compared to a current price of NT$40.15 — trading 78.5% below its estimated fair value. The current PS Ratio is 15.39, which is 86% below median its 10-year median of 106.61 and 71% above the Biotechnology industry median of 9.00. 3D Global Biotech's overall GF Score™ is 70/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For 3D Global Biotech (ROCO:6808), the current PS Ratio is 15.39 as of Jul. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Global Biotech (ROCO:6808) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Global Biotech stock appears to be undervalued.
The current stock price of NT$40.15 is trading 78.5% below its estimated GF Value™ of NT$186.52.
GuruFocus considers 3D Global Biotech to be Significantly Undervalued.
Key valuation signals for ROCO:6808:
PS Ratio: 15.39 (86% below median its 10-year median of 106.61)
GF Value™: NT$186.52 vs. price of NT$40.15 (78.5% below fair value)
Industry Position: 71% above the Biotechnology median (#572 of 930)
No single metric tells the full story. See the ROCO:6808 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Global Biotech Inc is engaged in the research and development of high-end medical equipment and biological 3D printing technology and the sale of medical Materials and other related products.
70GF Score
Get the complete analysis for ROCO:6808
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6808 has been successfully added to your 
